Dopamine Reuptake Inhibitors (DRIs) are a class of medications that block the reabsorption of the neurotransmitter dopamine in the brain. By preventing dopamine from being reabsorbed, these drugs increase its availability in the synaptic cleft, which can enhance mood and motivation. DRIs are often used to treat conditions like depression and attention deficit hyperactivity disorder (ADHD). These medications work by targeting the dopamine transporter, a protein responsible for the reuptake process. By inhibiting this transporter, DRIs can lead to increased dopamine levels, potentially improving symptoms associated with low dopamine activity. Common examples of DRIs include bupropion and methylphenidate.